Abstract

The present disclosure relates to solid state forms of Reproxalap salts, processes for the preparation thereof, pharmaceutical formulations/compositions thereof, and methods of use thereof.

IPC Classes  ?

• C07D 215/38 - Nitrogen atoms

Abstract

The present disclosure encompasses solid state forms of Nirogacestat salts, in embodiments crystalline polymorphs of Nirogacestat salts, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• A61K 31/417 - Imidazole-alkylamines, e.g. histamine, phentolamine
• C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Abstract

The present disclosure encompasses solid state forms of Ensifentrine, in embodiments crystalline polymorphs or salts of Ensifentrine, particularly Ensifentrine ethane-1.2-disulfonate, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

The present disclosure encompasses solid state forms of Vericiguat, in embodiments crystalline polymorphs of Vericiguat, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems

Abstract

The present disclosure relates to solid state forms of Telatinib and Telatinib mesylate, processes for their preparation, and pharmaceutical compositions thereof (I). The present disclosure relates to solid state forms of Telatinib and Telatinib mesylate, processes for their preparation, and pharmaceutical compositions thereof (I).

IPC Classes  ?

• C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• A61K 31/5025 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems

Abstract

The present disclosure relates to solid state forms of Lumateperone besylate. processes for preparation thereof and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 471/16 - Peri-condensed systems
• C07C 309/29 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings

Abstract

Solid state forms of Abexinostat salts and of Abexinostat tosylate:p-toluenesulfonic acid monohydrate complex, processes for preparation thereof, pharmaceutical compositions and uses thereof are disclosed.

IPC Classes  ?

• C07D 307/85 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• C07C 57/15 - Fumaric acid
• C07C 309/04 - Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
• C07C 309/05 - Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
• C07C 309/30 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups

Abstract

The present disclosure encompasses crystalline polymorphs of Rigosertib Sodium, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07C 317/28 - Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton

Abstract

The present disclosure relates to a process for the preparation of Sotorasib and salts thereof useful as a pharmaceutical active compound. The present disclosure also relates to intermediates for the preparation of Sotorasib and salts thereof. Further, the present disclosure encompasses solid state forms of Sotorasib, in embodiments crystalline polymorphs of Sotorasib, processes for preparation thereof, and pharmaceutical compositions thereof. Also provided are processes for the preparation of Sotorasib.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

The present disclosure encompasses a solid state form of Centanafadine HCl, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 209/52 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole

Abstract

The present disclosure encompasses solid state forms of Lanifibranor, in embodiments crystalline polymorphs of Lanifibranor, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/428 - Thiazoles condensed with carbocyclic rings

Abstract

The present disclosure encompasses solid state forms of Tapinarof, in embodiments crystalline polymorphs or co-crystals of Tapinarof, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07C 39/21 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic part, with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
• A61K 31/05 - Phenols

Abstract

The present disclosure encompasses solid state forms of Tideglusib, in embodiments crystalline polymorphs or salts or co-crystals of Tideglusib, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• A61K 31/433 - Thiadiazoles

Goods & Services

(1) Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations; pharmaceutical preparations, namely, anti-psychotics.

Goods & Services

(1) Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations; pharmaceutical preparations, namely, anti-psychotics.

Goods & Services

(1) Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations; pharmaceutical preparations, namely, anti-psychotics.

Goods & Services

(1) Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations; pharmaceutical preparations, namely, anti-psychotics.

Goods & Services

(1) Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations; pharmaceutical preparations, namely, anti-psychotics.

Abstract

The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 31/4045 - Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• C07K 16/26 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones

Goods & Services

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations; pharmaceutical preparations, namely, anti-psychotics.

Goods & Services

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations; pharmaceutical preparations, namely, anti-psychotics.

Goods & Services

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations; pharmaceutical preparations, namely, anti-psychotics.

Goods & Services

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations; pharmaceutical preparations, namely, anti-psychotics.

Goods & Services

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations; pharmaceutical preparations, namely, anti-psychotics.

Goods & Services

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations; pharmaceutical preparations, namely, anti-psychotics.

Goods & Services

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations; pharmaceutical preparations, namely, anti-psychotics.

Goods & Services

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations; pharmaceutical preparations, namely, anti-psychotics.

Goods & Services

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations; pharmaceutical preparations, namely, anti-psychotics.

Goods & Services

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations; pharmaceutical preparations, namely, anti-psychotics.

Abstract

The present disclosure provides new procedures and intermediates for the preparation of Zanubrutinib.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems

Abstract

The present disclosure encompasses solid state forms of Belumosudil, in embodiments crystalline polymorphs of Belumosudil or salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Goods & Services

Pharmaceutical preparations for the prevention and treatment of inflammatory and autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders (skin), musculoskeletal diseases and disorders; Pharmaceutical preparations for the prevention and treatment of central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations.

Goods & Services

(1) Pharmaceutical preparations for the prevention and treatment of inflammatory and autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders (skin), musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations.

Goods & Services

Pharmaceutical products, namely, drug delivery agents in the form of co-polymers or block co-polymers that facilitate the delivery of pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders of the skin, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; pharmaceutical preparations for use in the treatment of oncological and metabolic diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations

Goods & Services

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, immunological, infectious, inflammatory, menopausal, neurological, respiratory, urogenital, urological and viral diseases and disorders; Pharmaceutical preparations for treatment of the central nervous system; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of pain; pharmaceutical preparations, namely, pharmaceuticals preparations for the treatment of ophthalmic diseases; pharmaceuticals preparations for the treatment of ophthalmic diseases and conditions

Goods & Services

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, immunological, infectious, inflammatory, menopausal, neurological, respiratory, urogenital, urological and viral diseases and disorders; Pharmaceutical preparations for treatment of the central nervous system; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of pain; pharmaceutical preparations, namely, pharmaceuticals preparations for the treatment of ophthalmic diseases; pharmaceuticals preparations for the treatment of ophthalmic diseases and conditions

Goods & Services

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, immunological, infectious, inflammatory, menopausal, neurological, respiratory, urogenital, urological and viral diseases and disorders; Pharmaceutical preparations for treatment of the central nervous system; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of pain; pharmaceutical preparations, namely, pharmaceuticals preparations for the treatment of ophthalmic diseases; pharmaceuticals preparations for the treatment of ophthalmic diseases and conditions

Goods & Services

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, immunological, infectious, inflammatory, menopausal, neurological, respiratory, urogenital, urological and viral diseases and disorders; Pharmaceutical preparations for treatment of the central nervous system; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of pain; pharmaceutical preparations, namely, pharmaceuticals preparations for the treatment of ophthalmic diseases; pharmaceuticals preparations for the treatment of ophthalmic diseases and conditions

Goods & Services

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, immunological, infectious, inflammatory, menopausal, neurological, respiratory, urogenital, urological and viral diseases and disorders; Pharmaceutical preparations for treatment of the central nervous system; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of pain; pharmaceutical preparations, namely, pharmaceuticals preparations for the treatment of ophthalmic diseases; pharmaceuticals preparations for the treatment of ophthalmic diseases and conditions

Goods & Services

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, immunological, infectious, inflammatory, menopausal, neurological, respiratory, urogenital, urological and viral diseases and disorders; Pharmaceutical preparations for treatment of the central nervous system; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of pain; pharmaceutical preparations, namely, pharmaceuticals preparations for the treatment of ophthalmic diseases; pharmaceuticals preparations for the treatment of ophthalmic diseases and conditions

Goods & Services

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, immunological, infectious, inflammatory, menopausal, neurological, respiratory, urogenital, urological and viral diseases and disorders; Pharmaceutical preparations for treatment of the central nervous system; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of pain; pharmaceutical preparations, namely, pharmaceuticals preparations for the treatment of ophthalmic diseases; pharmaceuticals preparations for the treatment of ophthalmic diseases and conditions

Goods & Services

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, immunological, infectious, inflammatory, menopausal, neurological, respiratory, urogenital, urological and viral diseases and disorders; Pharmaceutical preparations for treatment of the central nervous system; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of pain; pharmaceutical preparations, namely, pharmaceuticals preparations for the treatment of ophthalmic diseases; pharmaceuticals preparations for the treatment of ophthalmic diseases and conditions

Abstract

The present disclosure encompasses solid state forms of Capivasertib, in embodiments crystalline polymorphs, salts and co-crystals of Capivasertib, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems

Abstract

The present disclosure relates to solid state forms of Erdafitinib salts, processes for preparation thereof, processes for preparation of Erdafitinib and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages

Abstract

The disclosure notably relates to a syringe. The syringe comprises a barrel forming a medicament reservoir therein. The medicament reservoir is capable of fluid communication with a needle hub at a distal end thereof. The syringe further comprises a stopper. The stopper seals the medicament reservoir. The stopper is slidable inside the barrel toward the distal end. The syringe further comprises a plunger assembly. The plunger assembly comprises a plunger rod and a spring. The spring is arranged between a distal end of the plunger rod and the stopper. The spring is configured to transmit to the stopper a forward axial movement of the plunger rod, thereby causing a forward axial movement of the stopper into the medicament reservoir in order to expel the medicament through the needle hub. The plunger rod is axially movable between a proximal extremal position and a distal extremal position. The spring is in a relaxed state when the plunger rod is at the proximal extremal position.

IPC Classes  ?

• A61M 5/48 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for varying, regulating, indicating or limiting injection pressure
• A61M 5/315 - Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod; Appliances on the rod for facilitating dosing

Abstract

The present disclosure encompasses solid state forms of Pralsetinib and of Pralsetinib salts and co-crystals, in embodiments crystalline polymorphs of Pralsetinib, Pralsetinib salts and co-crystals processes for preparation thereof, and pharmaceutical compositions thereof. The present disclosure encompasses solid state forms of Pralsetinib and of Pralsetinib salts and co-crystals, in embodiments crystalline polymorphs of Pralsetinib, Pralsetinib salts and co-crystals processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

The present disclosure encompasses solid state forms of Belumosudil, in embodiments crystalline polymorphs of Belumosudil or salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Disclosed are solid state forms of lumateperone ditosylate, uses thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 471/16 - Peri-condensed systems
• C07C 309/30 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups

Abstract

The present disclosure encompasses solid state forms of Trilaciclib and of Trilaciclib salts, in embodiments crystalline polymorphs of Trilaciclib and of Trilaciclib salts, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 487/20 - Spiro-condensed systems

Abstract

The present disclosure encompasses solid state forms of Mirdametinib, particularly to Mirdametinib complexes. In embodiments the present disclosure encompasses processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07C 259/10 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
• A61P 35/00 - Antineoplastic agents
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol

Abstract

The present disclosure encompasses solid state forms of Resmetirom, in embodiments crystalline polymorphs of Resmetirom, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir

Abstract

The present disclosure encompasses solid state forms of Gefapixant, in embodiments crystalline polymorphs or salts or co-crystals of Gefapixant, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 239/48 - Two nitrogen atoms

Abstract

Solid state forms of SEP-363856 HBr, SEP-363856 Fumarate, SEP-363856 R-camsylate and SEP-363856 S-camsylate and processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 495/04 - Ortho-condensed systems

Abstract

The present disclosure encompasses processes for the preparation of (S)-Finerenone.

IPC Classes  ?

• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

The present disclosure encompasses a solid state form of Mavacamten, in embodiments a crystalline polymorph of Mavacamten, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 239/545 - Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

Abstract

The present disclosure encompasses solid state forms of AT-001, in embodiments crystalline polymorphs of AT-001 or salts or co-crystals of AT-001, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems

Abstract

The invention relates to a vial adaptor. The vial adaptor comprises a syringe connection port. The syringe connection port is configured to be connected to a syringe. The vial adaptor further comprises a vial connection port. The vial connection port comprises a skirt and a spike. The spike has a lumen forming a fluid channel. The vial adaptor further comprises a conduit configured to provide fluid flow between the syringe connection port and the vial connection port. The vial adaptor further comprises a valve for selectively blocking and allowing fluid flow between the syringe and the conduit through the syringe connection port when the syringe is connected to the syringe connection port. This constitutes an improved solution for connecting a syringe and a vial.

IPC Classes  ?

• A61J 1/20 - Arrangements for transferring fluids, e.g. from vial to syringe

Abstract

The present disclosure encompasses solid state forms of LX9211, salts and cocrystals thereof, in embodiments processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 213/65 - One oxygen atom attached in position 3 or 5
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone

Abstract

The present disclosure encompasses solid state forms of Tolebrutinib and of Tolebrutinib salts, in embodiments crystalline polymorphs of Tolebrutinib and of Tolebrutinib salts, processes for preparation thereof, and pharmaceutical compositions thereof. In particular, the present invention discloses crystalline polymorphs, salts and co-crystals of Tolebrutinib.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Abstract

The present disclosure encompasses solid state forms of Fezolinetant, including salts and cocrystals of Fezolinetant, in embodiments crystalline polymorphs of Fezolinetant, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems

Abstract

The present disclosure encompasses solid state forms of Trilaciclib and Trilaciclib citrate salt, in embodiments polymorphs of Trilaciclib and Trilaciclib citrate salt, processes for preparation thereof, pharmaceutical compositions and uses thereof.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07D 487/20 - Spiro-condensed systems
• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

The present disclosure encompasses solid state forms of Gusacitinib, in embodiments crystalline polymorphs of Gusacitinib, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 17/00 - Drugs for dermatological disorders

Abstract

The present disclosure relates to Danicopan solid state forms, processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

IPC Classes  ?

• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid

Abstract

The present disclosure encompasses a process for chiral resolution of racemic amines, particularly ethyl 2-(4-((tert-butoxycarbonyl)amino)phenyl)piperidine-3-carboxylate, into its desired isomer, ethyl (2R,3S)-2-(4-((tert-butoxycarbonyl)amino)phenyl)-piperidine-3-carboxylate, which is an intermediate useful in the synthesis of Avacopan.

IPC Classes  ?

• C12P 13/00 - Preparation of nitrogen-containing organic compounds
• C12P 17/12 - Nitrogen as only ring hetero atom containing a six-membered hetero ring
• C12N 9/06 - Oxidoreductases (1.), e.g. luciferase acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
• C07D 221/00 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups

Abstract

Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/06 - Antimigraine agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/06 - Antimigraine agents

Abstract

The disclosure is directed to olanzapine, compositions and methods of use thereof, wherein the olanzapine exhibits good flowability and syringeability.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders

Abstract

The present disclosure encompasses solid state forms and co-crystals of Ensartinib and of Ensartinib salts, in embodiments crystalline polymorphs of Ensartinib and of Ensartinib salts and co-crystals, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 237/22 - Nitrogen and oxygen atoms

Abstract

The present invention relates to safe and improved processes for the preparation of substantially pure intermediates of formula Va and their use in the synthesis of Ripretinib and salts thereof.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems

Abstract

The present disclosure encompasses a solid-state form of Lotilaner, in embodiment processes for preparation thereof, and pharmaceutical compositions thereof. The present disclosure further encompasses Lotilaner salts and their solid state forms, as well as processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61P 27/00 - Drugs for disorders of the senses
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

The present disclosure encompasses solid state forms of AMG-510 (Sotorasib), in embodiments crystalline polymorphs of AMG-510, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems

Abstract

The present disclosure encompasses solid state forms of Nirogacestat salts, in embodiments crystalline polymorphs of Nirogacestat salts, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 233/88 - Nitrogen atoms, e.g. allantoin

Abstract

The present disclosure encompasses novel solid state forms of Aprocitentan, Aprocitentan salts and Aprocitentan co-crystals, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present disclosure encompasses solid state forms of Nirogacestat salts, in embodiments crystalline polymorphs of Nirogacestat salts, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 233/88 - Nitrogen atoms, e.g. allantoin
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure relates to solid state forms of Voclosporin and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.

IPC Classes  ?

• C07K 7/64 - Cyclic peptides containing only normal peptide links

Abstract

An auto injector apparatus includes a syringe and an auto injector. The syringe includes a barrel holding a therapeutic fluid including an anti-calcitonin gene-related peptide (anti-CGRP) antibody. The syringe also includes a stopper disposed within the barrel and the stopper moves axially within the barrel between a first position and a second position to expel at least some of the therapeutic fluid from the syringe. The auto injector includes a rod that abuts the stopper and an injection spring that drives the rod to apply a dispensing force through the rod to the stopper. The dispensing force includes a first dispensing force of between 20 N and 40 N and a second dispensing force of between 12 N and 20 N. The injection spring initially applies the first dispensing force and then applies the second dispensing force to move the stopper to the second position.

IPC Classes  ?

• A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
• A61M 5/315 - Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod; Appliances on the rod for facilitating dosing

Abstract

The present disclosure relates to a solid state form of Tafamidis, processes for preparation thereof and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 263/57 - Aryl or substituted aryl radicals
• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 31/423 - Oxazoles condensed with carbocyclic rings

Abstract

The present disclosure encompasses solid state forms of Ensifentrine, in embodiments crystalline polymorphs or salts of Ensifentrine, particularly Ensifentrine ethane-1,2-disulfonate, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 37/08 - Antiallergic agents
• A61P 11/06 - Antiasthmatics

Abstract

The present disclosure encompasses solid state forms of Belumosudil, in embodiments crystalline polymorphs of Belumosudil or salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention concerns a co-crystal of Elacestrant dihydrochloride and urea, its use in the preparation of another solid state form of Elecestrant or a salt thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07C 217/84 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
• C07C 275/02 - Salts; Complexes; Addition compounds
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61P 35/00 - Antineoplastic agents

Goods & Services

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations.

Goods & Services

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations.

Goods & Services

(1) Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations.

Goods & Services

(1) Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations.

Goods & Services

(1) Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations.

Goods & Services

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations.

Abstract

The present disclosure relates to safe and efficient processes for the synthesis of Glasdegib or salts thereof, preferably Glasdegib Maleate. The present disclosure also encompasses solid state forms of Glasdegib maleate, in embodiments crystalline polymorphs of Glasdegib maleate, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond

Goods & Services

(1) Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations.

Goods & Services

(1) Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations.

Goods & Services

(1) Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations.

Goods & Services

Pharmaceutical preparations for the prevention and treatment of central and peripheral nervous system diseases and disorders; none of the aforesaid goods to include preparations applied to the skin.

Goods & Services

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases (excluding preparations for the treatment of allergies) and disorders (excluding preparations for the treatment of allergies), blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases (excluding preparations for the treatment of allergies) and disorders (excluding preparations for the treatment of allergies), musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders (excluding preparations for the treatment of allergies), urogenital diseases and disorders, and urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations; pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, excluding preparations for the treatment of allergies and an analgesic oral mucosa gel for treating oral mucosa diseases and gingivitis; pharmaceutical preparations for use in the treatment of infectious diseases and inflammatory conditions, excluding preparations for the treatment of allergies and an analgesic oral mucosa gel for treating oral mucosa diseases and gingivitis.

Goods & Services

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations

Goods & Services

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations

Goods & Services

Pharmaceutical preparations for the prevention and treatment of central and peripheral nervous system diseases and disorders; none of the aforesaid goods to include preparations applied to the skin

Goods & Services

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations

Abstract

Solid state forms of Mitapivat, Mitapivat hemisulfate, Mitapivat HCl, Mitapivat phosphate, Mitapivat hemisulfate:ascorbic acid and Mitapivat hemisulfate:adipic acid, processes for preparation thereof, pharmaceutical compositions there-of, and uses thereof are disclosed.

IPC Classes  ?

• C07D 215/36 - Sulfur atoms

Abstract

The present disclosure encompasses solid state forms of Asciminib and salts thereof, in embodiments crystalline poly-morphs of Asciminib and salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

The present invention encompasses salts and solid state forms of Ipatasertib and pharmaceutical compositions thereof.

IPC Classes  ?

• C07D 239/70 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
• A61P 35/00 - Antineoplastic agents
• A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine